Skip to main content
Premium Trial:

Request an Annual Quote

Santaris Regains Ownership of Cancer Programs Licensed to Enzon

Premium

Santaris Pharma said this week that partner Enzon has returned the rights to all of the data and intellectual property related to the locked nucleic acid drugs the companies were developing under a long-term partnership in cancer.

Santaris said it will also receive an undisclosed amount of money as part of the arrangement, and did not provide reasons behind Enzon's decision. None of the products the companies were working on were microRNA-related.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.